NUDT1 and adenocarcinoma: To further validate the above molecular dynamic conclusions of docking emodin with MTH1 protein, human NSCLC cell lines NCI-H-520 (squamous cell carcinoma), NCI-H-460 (large cell carcinoma), and A-549 (adenocarcinoma) were treated with emodin (25, 50 and 75 μM) or vehicle (DMSO < 0.5% volume) for 24, 48, and 72 h.